Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19984866 | 0.86 | CYP1A2 (0.49) | CYP1A2SIGMAR1POLBIDO1ATM | |
| SCHEMBL13116633 | 0.85 | CYP1A2 (0.44) | CYP1A2SIGMAR1POLBIDO1ATM | |
| SCHEMBL3315502 | 0.78 | CYP1A2 (0.45) | CYP1A2SIGMAR1POLBIDO1ATM | |
| SCHEMBL3348647 | 0.78 | CYP1A2 (0.47) | CYP1A2IDO1HSD17B1NOTUM | |
| SCHEMBL30618514 | 0.78 | CYP1A2 (0.47) | CYP1A2IDO1HSD17B1NOTUM | |
| SCHEMBL5468751 | 0.76 | ALDH1A1 (0.49) | CYP1A2 | |
| SCHEMBL19838624 | 0.75 | CYP1A2 (0.44) | CYP1A2SIGMAR1POLBIDO1KCNH2 | |
| SCHEMBL29960504 | 0.75 | CYP1A2 (0.44) | CYP1A2SIGMAR1POLBIDO1KCNH2 | |
| SCHEMBL9181002 | 0.75 | ALDH1A1 (0.46) | CYP1A2IDO1KCNH2GRIN2B | |
| SCHEMBL11769040 | 0.74 | CYP1A2 (0.46) | CYP1A2SIGMAR1POLBIDO1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7226942-B2 | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226942-B2 | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| US-7226942-B2 | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-05 | — | — | US | disclosed |
| WO-2006055462-A1 | 2-AMINO-4-FUNCTIONALIZED TETRALIN DERIVATIVES AND RELATED GLYCOGEN PHOSPHORYLASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060111338-A1 | 2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111338-A1 | 2-Amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors | PYGM, PYGL, PYGB | CYP1A2 1743/4885SIGMAR1 1102/4885POLB 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.